These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 12814260)

  • 41. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51.
    Laack NN; Ballman KV; Brown PB; O'Neill BP;
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1429-39. PubMed ID: 16863926
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients.
    Guha-Thakurta N; Damek D; Pollack C; Hochberg FH
    J Neurooncol; 1999 Jul; 43(3):259-68. PubMed ID: 10563432
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience.
    Ney DE; Reiner AS; Panageas KS; Brown HS; DeAngelis LM; Abrey LE
    Cancer; 2010 Oct; 116(19):4605-12. PubMed ID: 20572045
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome.
    Glass J; Gruber ML; Cher L; Hochberg FH
    J Neurosurg; 1994 Aug; 81(2):188-95. PubMed ID: 8027800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
    Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
    Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
    Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
    Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
    Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
    Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary CNS lymphoma: a clinician's guide.
    Schäfer N; Glas M; Herrlinger U
    Expert Rev Neurother; 2012 Oct; 12(10):1197-206. PubMed ID: 23082736
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma.
    Nguyen PL; Chakravarti A; Finkelstein DM; Hochberg FH; Batchelor TT; Loeffler JS
    J Clin Oncol; 2005 Mar; 23(7):1507-13. PubMed ID: 15735126
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term survival in AIDS-related primary central nervous system lymphoma.
    Gupta NK; Nolan A; Omuro A; Reid EG; Wang CC; Mannis G; Jaglal M; Chavez JC; Rubinstein PG; Griffin A; Abrams DI; Hwang J; Kaplan LD; Luce JA; Volberding P; Treseler PA; Rubenstein JL
    Neuro Oncol; 2017 Jan; 19(1):99-108. PubMed ID: 27576871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
    Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
    J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study.
    Montemurro M; Kiefer T; Schüler F; Al-Ali HK; Wolf HH; Herbst R; Haas A; Helke K; Theilig A; Lotze C; Hirt C; Niederwieser D; Schwenke M; Krüger WH; Dölken G
    Ann Oncol; 2007 Apr; 18(4):665-71. PubMed ID: 17185743
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [High-dose methotrexate followed by whole-brain irradiation for primary central nervous system lymphoma patients--a retrospective study in a single institute].
    Usui N; Dobashi N; Yano S; Yahagi Y; Takei Y; Otsubo H; Takahara S; Yamaguchi Y; Saito T; Minami J; Kamiyama Y; Morikawa N; Machishima T; Osawa H; Aiba K
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1277-82. PubMed ID: 20647709
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
    J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
    Yamanaka R; Shinbo Y; Sano M; Homma J; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Morii K; Onda K; Tanaka R
    Leuk Lymphoma; 2007 Jun; 48(6):1119-26. PubMed ID: 17577775
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
    J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma.
    Hottinger AF; DeAngelis LM; Yahalom J; Abrey LE
    Neurology; 2007 Sep; 69(11):1178-82. PubMed ID: 17846417
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma.
    Basso U; Brandes AA
    Eur J Cancer; 2002 Jul; 38(10):1298-312. PubMed ID: 12091059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary central nervous system lymphoma.
    Mohile NA; Abrey LE
    Semin Radiat Oncol; 2007 Jul; 17(3):223-9. PubMed ID: 17591569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.